Biosplice Therapeutics Stock

Tissue-Level Regeneration

Sign up today and learn more about Biosplice Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

Starling group


San Diego CA, US

Total Funding


About Biosplice Therapeutics Stock

Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.


Funding History

February 2021$60.0M
March 2021$60.0M


Chief Executive Officer

Samikoglu Cevdet

Chief Financial Officer

Horsley Erich


fiercebiotech - May, 15 2019

2. Samumed

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: